220 related articles for article (PubMed ID: 28387096)
41. The impact of family history on non-medullary thyroid cancer.
Nixon IJ; Suárez C; Simo R; Sanabria A; Angelos P; Rinaldo A; Rodrigo JP; Kowalski LP; Hartl DM; Hinni ML; Shah JP; Ferlito A
Eur J Surg Oncol; 2016 Oct; 42(10):1455-63. PubMed ID: 27561845
[TBL] [Abstract][Full Text] [Related]
42. Familial Non-Medullary Thyroid Cancer Represents an Independent Risk Factor for Increased Cancer Aggressiveness: A Retrospective Analysis of 74 Families.
Tavarelli M; Russo M; Terranova R; Scollo C; Spadaro A; Sapuppo G; Malandrino P; Masucci R; Squatrito S; Pellegriti G
Front Endocrinol (Lausanne); 2015; 6():117. PubMed ID: 26284028
[TBL] [Abstract][Full Text] [Related]
43. CHEK2 germline variants identified in familial nonmedullary thyroid cancer lead to impaired protein structure and function.
Pires C; Marques IJ; Valério M; Saramago A; Santo PE; Santos S; Silva M; Moura MM; Matos J; Pereira T; Cabrera R; Lousa D; Leite V; Bandeiras TM; Vicente JB; Cavaco BM
J Biol Chem; 2024 Mar; 300(3):105767. PubMed ID: 38367672
[TBL] [Abstract][Full Text] [Related]
44. [Clinical features of 17 patients with familial non medullary thyroid carcinoma].
Mosso L; Velasco S; Salazar I; Solar A; González H; Cardona B; Fardella C; González G; López JM; Rodríguez JA; Cruz F; Arteaga E
Rev Med Chil; 2007 Jun; 135(6):718-24. PubMed ID: 17728897
[TBL] [Abstract][Full Text] [Related]
45. Genetic susceptibility to hereditary non-medullary thyroid cancer.
Kamani T; Charkhchi P; Zahedi A; Akbari MR
Hered Cancer Clin Pract; 2022 Mar; 20(1):9. PubMed ID: 35255942
[TBL] [Abstract][Full Text] [Related]
46. Susceptibility Genes and Chromosomal Regions Associated With Non-Syndromic Familial Non-Medullary Thyroid Carcinoma: Some Pathogenetic and Diagnostic Keys.
Sánchez-Ares M; Cameselle-García S; Abdulkader-Nallib I; Rodríguez-Carnero G; Beiras-Sarasquete C; Puñal-Rodríguez JA; Cameselle-Teijeiro JM
Front Endocrinol (Lausanne); 2022; 13():829103. PubMed ID: 35295987
[TBL] [Abstract][Full Text] [Related]
47. Familial history of non-medullary thyroid cancer is an independent prognostic factor for tumor recurrence in younger patients with conventional papillary thyroid carcinoma.
Lee YM; Yoon JH; Yi O; Sung TY; Chung KW; Kim WB; Hong SJ
J Surg Oncol; 2014 Feb; 109(2):168-73. PubMed ID: 24132694
[TBL] [Abstract][Full Text] [Related]
48. BROX haploinsufficiency in familial nonmedullary thyroid cancer.
Pasquali D; Torella A; Accardo G; Esposito D; Del Vecchio Blanco F; Salvatore D; Sabatino P; Pacini F; Barbato F; Castagna MG; Cantara S; Nigro V
J Endocrinol Invest; 2021 Jan; 44(1):165-171. PubMed ID: 32385852
[TBL] [Abstract][Full Text] [Related]
49. Genetic aspects of familial thyroid cancer.
Morrison PJ; Atkinson AB
Oncologist; 2009 Jun; 14(6):571-7. PubMed ID: 19465682
[TBL] [Abstract][Full Text] [Related]
50. Clinical characteristics and outcome of familial nonmedullary thyroid cancer: a retrospective controlled study.
Robenshtok E; Tzvetov G; Grozinsky-Glasberg S; Shraga-Slutzky I; Weinstein R; Lazar L; Serov S; Singer J; Hirsch D; Shimon I; Benbassat C
Thyroid; 2011 Jan; 21(1):43-8. PubMed ID: 20954815
[TBL] [Abstract][Full Text] [Related]
51. Clinical Analysis of Familial Nonmedullary Thyroid Carcinoma.
Zhang Q; Yang S; Meng XY; Chen G; Pang RZ
World J Surg; 2016 Mar; 40(3):570-3. PubMed ID: 26711636
[TBL] [Abstract][Full Text] [Related]
52. [Next generation sequencing technology for susceptible gene screening in familial non-medullary thyroid carcinoma].
Dong L; Yu Y; Yu JP; Hao WJ; Zheng XQ; Cheng YN; Han L; Zhao JZ; Gao M
Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):24-28. PubMed ID: 28104029
[No Abstract] [Full Text] [Related]
53. Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series.
Alsanea O; Wada N; Ain K; Wong M; Taylor K; Ituarte PH; Treseler PA; Weier HU; Freimer N; Siperstein AE; Duh QY; Takami H; Clark OH
Surgery; 2000 Dec; 128(6):1043-50;discussion 1050-1. PubMed ID: 11114641
[TBL] [Abstract][Full Text] [Related]
54. Familial follicular cell-derived thyroid carcinoma.
Son EJ; Nosé V
Front Endocrinol (Lausanne); 2012; 3():61. PubMed ID: 22654876
[TBL] [Abstract][Full Text] [Related]
55. Familial non-medullary thyroid cancer: a matched-case control study.
Maxwell EL; Hall FT; Freeman JL
Laryngoscope; 2004 Dec; 114(12):2182-6. PubMed ID: 15564841
[TBL] [Abstract][Full Text] [Related]
56. [Hereditary thyroid carcinoma and its molecular diagnostics].
Dvořáková S; Václavíková E; Sýkorová V; Hálková T; Bendlová B
Cesk Patol; 2014 Apr; 50(2):81-6. PubMed ID: 24758503
[TBL] [Abstract][Full Text] [Related]
57. FOXE1 polymorphisms are associated with familial and sporadic nonmedullary thyroid cancer susceptibility.
Tomaz RA; Sousa I; Silva JG; Santos C; Teixeira MR; Leite V; Cavaco BM
Clin Endocrinol (Oxf); 2012 Dec; 77(6):926-33. PubMed ID: 22882326
[TBL] [Abstract][Full Text] [Related]
58. Identification of somatic TERT promoter mutations in familial nonmedullary thyroid carcinomas.
Marques IJ; Moura MM; Cabrera R; Pinto AE; Simões-Pereira J; Santos C; Menezes FD; Montezuma D; Henrique R; Rodrigues Teixeira M; Leite V; Cavaco BM
Clin Endocrinol (Oxf); 2017 Oct; 87(4):394-399. PubMed ID: 28502101
[TBL] [Abstract][Full Text] [Related]
59. Mapping of a gene predisposing to familial thyroid tumors with cell oxyphilia to chromosome 19 and exclusion of JUN B as a candidate gene.
Kraimps JL; Canzian F; Jost C; Menet E; Amati P; Levillian P; Harach R; Lesueur F; Barbier J; Romeo G; Bonneau D
Surgery; 1999 Dec; 126(6):1188-94. PubMed ID: 10598206
[TBL] [Abstract][Full Text] [Related]
60. Identification of
Jiang YJ; Xia Y; Hu YX; Han ZJ; Guo AY; Huang T
Thyroid; 2024 May; 34(5):583-597. PubMed ID: 38411500
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
